Payment overview · 2025
General Payments
$2,756.43
27 reported records · 11 companies
Healthcare provider profile · identity verified
Everald O. Manning, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1043295652
Verified facts
What the public records show
CMS Open Payments records show Everald O. Manning, M.D. received $2,756.43 in general payments during 2025 across 27 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $1,339.24 | 48.6% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,130.05 | 41.0% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.85 | 1.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.93 | 1.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.30 | 1.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.22 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.97 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.68 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.54 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.64 | 0.9% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.01 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $2,032.66 | 8 |
| Food and Beverage | $723.77 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.93 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.30 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $23.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 218 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
218 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 87 |
| Duloxetine Hcl | Duloxetine Hcl | 250 | 56 |
| Gabapentin | Gabapentin | 230 | 51 |
| Ozempic | Semaglutide | 218 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 45 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 192 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 184 | 67 |
| Montelukast Sodium | Montelukast Sodium | 165 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 52 |
| Pregabalin | Pregabalin | 164 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 60 |
| Telmisartan | Telmisartan | 155 | 35 |
| Farxiga | Dapagliflozin Propanediol | 139 | 29 |
| Tramadol Hcl | Tramadol Hcl | 135 | 43 |
| Losartan Potassium | Losartan Potassium | 131 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 40 |
| Alprazolam | Alprazolam | 120 | 19 |
| Trazodone Hcl | Trazodone Hcl | 112 | 32 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 106 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 29 |
| Methocarbamol | Methocarbamol | 103 | 22 |
| Prednisone | Prednisone | 103 | 46 |
| Omeprazole | Omeprazole | 100 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 35 |
| Furosemide | Furosemide | 90 | 31 |
| Buspirone Hcl | Buspirone Hcl | 76 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 76 | 19 |
| Ezetimibe | Ezetimibe | 75 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 20 |
| Carvedilol | Carvedilol | 71 | 16 |
| Jardiance | Empagliflozin | 66 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 22 |
| Spironolactone | Spironolactone | 62 | 17 |
| Mirtazapine | Mirtazapine | 60 | 19 |
| Potassium Chloride | Potassium Chloride | 56 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 17 |
| Metformin Hcl | Metformin Hcl | 53 | 16 |
| Myrbetriq | Mirabegron | 53 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 11 |
| Clonidine Hcl | Clonidine Hcl | 48 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Topiramate | Topiramate | 48 | 16 |
| Eliquis | Apixaban | 47 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 44 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 28 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 38 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 13 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 11 |
| Fluconazole | Fluconazole | 37 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 12 |
| Nifedipine Er | Nifedipine | 36 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 29 | suppressed |
| Famotidine | Famotidine | 28 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Lisinopril | Lisinopril | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 14 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Simvastatin | Simvastatin | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 13 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,756.43 · 27 records | Takeda Pharmaceuticals U.S.A., Inc. | ABRYSVO, COMIRNATY, FARXIGA, IBSRELA, KRYSTEXXA, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, TRELEGY ELLIPTA, Vafseo | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error